Who are Xaliproden (SR57746A)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, S (+) Ketamine, Intravenous anesthetic.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xaliproden-sr57746a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Xaliproden (SR57746A) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xaliproden (SR57746A) (Xaliproden (SR57746A)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuroprotective agent. Area: Neurology.

phase 3 Neuroprotective agent NMDA receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Xaliproden (SR57746A) (Xaliproden (SR57746A)) — Sanofi. Xaliproden acts as a neuroprotective agent by modulating the activity of the NMDA receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xaliproden (SR57746A) TARGET	Xaliproden (SR57746A)	Sanofi	phase 3	Neuroprotective agent	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
S (+) Ketamine	S (+) Ketamine	Asker & Baerum Hospital	marketed	NMDA receptor antagonist	NMDA receptor
Intravenous anesthetic	Intravenous anesthetic	University of Pennsylvania	marketed	GABA-A receptor agonist / NMDA receptor antagonist (class-dependent)	GABA-A receptor or NMDA receptor (varies by specific agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuroprotective agent class)

Bigespas LTD · 1 drug in this class
Capital Medical University · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
Rong Hu, MD · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xaliproden (SR57746A) — Competitive Intelligence Brief. https://druglandscape.com/ci/xaliproden-sr57746a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing